Pharmacologic Substance
MacroGenics Reviews Safety Protocols Following Three Patient Deaths in Prostate Cancer Drug Trial
MacroGenics, Phase 2 trial, prostate cancer, patient deaths, safety review, margetuximab, bispecific antibody
Royalty Pharma Invests $525 Million in Sanofi-Licensed Multiple Sclerosis Therapy Royalties and Milestones
Royalty Pharma, Sanofi, multiple sclerosis therapy, royalties, milestones, investment, healthcare, pharmaceuticals, licensing
Takeda Pharmaceuticals Revises Profit Forecast Due to Vyvanse Patent Expiration, Plans $900M Restructuring by 2024
Takeda Pharmaceuticals, Vyvanse, patent expiration, profit outlook, restructuring, ADHD medication
Novo Nordisk and Metaphore Pharmaceuticals Join Forces in a $600 Million Partnership to Pioneer Innovative Obesity Treatments
Novo Nordisk, Metaphore Pharmaceuticals, obesity drugs, next-generation treatments, $600 million deal, partnership, pharmaceutical collaboration, weight loss medications, metabolic disorders.
Verona Pharma Prepares $650 Million Funding Pool for Ensifentrine Launch Ahead of FDA Decision
Verona Pharma, COPD, Ensifentrine, FDA, funding pool, launch, clinical trials, chronic obstructive pulmonary disease
Keytruda Fails to Show Significant Benefit in Newly Diagnosed Endometrial Cancer Patients
Keytruda, endometrial cancer, clinical trial, newly diagnosed, immunotherapy, treatment, cancer therapy, clinical outcomes.
Takeda Pharmaceuticals Streamlines Operations with Digital Transformation and Workforce Restructuring
Takeda Pharmaceuticals, job cuts, digital transformation, workforce restructuring, operational efficiency, innovation, healthcare industry.
Evaluation of Keytruda Combined with Chemotherapy as Post-Surgical Treatment in Newly Diagnosed Endometrial Cancer Shows Limited Efficacy
Keytruda, Merck, endometrial cancer, post-surgical therapy, newly diagnosed, chemotherapy, clinical trial, limited efficacy.
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.
Uzedy, Teva, and MedinCell’s Collaborative Effort Yields Success in Phase 3 Trials for Long-Acting Schizophrenia Treatment
Uzedy, Teva, MedinCell, long-acting, schizophrenia, phase 3 trials, treatment, collaboration, mental health, neuroscience, psychiatry, injectable medication.